---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-034544"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2025-07-08T23:59:59+00:00"
generated_at: "2026-05-18T09:06:38.463210+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Absci appoints Mary Szela to Board effective July 7, 2025; grants 178,400 share option

## Summary
- Mary Szela appointed as Class III director; board expanded from six to seven members.
- Receives initial option grant for 178,400 shares at closing price on grant date, vesting monthly over three years.
- Will receive $40,000 annual cash retainer under Non-Employee Director Compensation Policy.
- Szela currently serves as CEO, President and Director of Trisalus Life Sciences.

## SEC filing metadata
- accession: 0001628280-25-034544
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2025-07-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828025034544/0001628280-25-034544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828025034544/absc-20250707.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-034544
- JSON: https://secwatch.observer/filing/0001628280-25-034544.json
- Plain text: https://secwatch.observer/filing/0001628280-25-034544.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.